A customer had reported a false negative ctx-m marker while utilizing verigene bc-gn assay.The patient was admitted on (b)(6) 2020 due to anasarca, the patient had expired on (b)(6) 2020 at 2:14 pm.The cause of death reported by the customer is septic and cardiogenic shock.Patient was on levofloxacin and doxycycline since admission.Meropenem and linezolid started (b)(6) 2020 around 1 am at the patient time of death, the medications (meropenem and linezolid) were removed from the patients treatment and no longer administered.Verigene bc-gn assay run on (b)(6) 2020, patient expired the same day; 4 hours after verigene result completed of septic like symptoms.The customer reported that the treatment was not amended due to the verigene reporting.The investigation is ongoing and if additional information becomes available, a follow-up report will be submitted.
|
A customer had reported a false negative ctx-m marker while utilizing verigene bc-gn assay on (b)(6) 2020.On (b)(6) 2020, after further investigation it was determined that the device was performing per performance specification per the package insert, and there was no indication of a device malfunction.
|